In conclusion, we have identified a series of combinations that can improve the response to BET inhibitors in lymphomas, and we have identified LRRK2 as a gene essential for lymphomas and as a putative novel target for the development of antilymphoma agents. The gene discussed is LRRK2; the disease is lymphoma.